Press Releases
Press releases from hepCoalition and partner organizations.
Materials in this section
Treatment Action Group Fiercely Condemns the New Administration’s War on Science
TAG is disgusted and appalled by the new presidential administration’s flagrant attack on science. These hostile and reckless actions will hobble the fight against HIV, TB, and HCV, worsen human health, and weaken communities for decades to come. More
‘Time for $5’ Campaign Delivers 206,937 Signatures to Danaher Demanding a $5 Price for Their Medical Tests
US test maker Cepheid and parent corporation Danaher have ignored global calls for price reductions and have broken their promise from one year ago to be transparent about what it costs to make their medical tests. More
MSF and Partners Protest Medical Test Maker Cepheid and Danaher at International AIDS Conference
Time for $5 Campaign demands Cepheid reduce price of HIV, TB and hepatitis C tests to $5 each. More
Danaher Continues to Charge Exorbitant Prices for Lifesaving Medical Tests Despite Urgent Demands for Price Reductions by Several Ministries of Health
Several Ministries of Health have written to Danaher requesting that the price of the tests for XDR-TB, HIV and hepatitis — currently priced at $14.90 per test cartridge — also be lowered to no more than $7.97. More
Treatment for Hepatitis C: The Patent System is Standing in the Way of Access to Medicine
Following the appeal filed by AIDES, Médecins du Monde and Médecins sans Frontières, the European Patent Office has decided to uphold the patent of sofosbuvir, hindering the launch of an affordable generic version of the drug in Europe. More
TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus
Ravidasvir is the first HCV cure to be developed through South-South collaboration and with funding and clinical support from non-profit organizations. It is now recommended for use in combination with sofosbuvir as an alternative pangenotypic DAA. More
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
Advocates Urge Cepheid to Reinstate Plans to Commercialize GeneXpert Omni
Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni. More
Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
Hepatitis C PACT will work in Latin America, Asia, Africa, and Eastern Europe — collaborating with “champion countries” that are already revolutionizing hepatitis care. More
Advocates Demand Continuous Catalytic Investment Towards Viral Hepatitis Elimination
An open letter sent to Unitaid demands continuous investment towards HBV and HCV elimination, and to address the needs of 354 million people living with viral hepatitis worldwide. More
